Cohort1: VXA-A1.1
|
Administration route |
oral|intramuscular injection |
Pts |
71 |
Age |
Adult |
Outcome |
Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus:17(29.3%) |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
31978354
|
|
Cohort2: Fluzone
|
Administration route |
oral|intramuscular injection |
Pts |
72 |
Age |
Adult |
Outcome |
Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus:19(35.2%) |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
31978354
|
|
Cohort3: Placebo
|
Administration route |
oral|intramuscular injection |
Pts |
36 |
Age |
Adult |
Outcome |
Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus:15(48.4%) |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
31978354
|
|